Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that finasteride is a viable first-line treatment for moderate uncomplicated benign prostatic hyperplasia, particularly in patients with larger prostates, by significantly reducing acute urinary retention and the need for surgery.

This article updates Japanese guidelines for diagnosing and treating male and female-pattern hair loss, recommending specific drugs and therapies while advising against certain treatments for female-pattern hair loss.

This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

This study found that long-term dutasteride therapy in men with benign prostatic hyperplasia worsened erectile dysfunction, reduced testosterone levels, and increased blood glucose and lipid profile, indicating negative metabolic impacts.

This study found that long-term finasteride therapy in men with BPH worsened erectile dysfunction and reduced testosterone levels, while these effects were not observed with tamsulosin.

This study found that MENT is 10 times more potent than testosterone in suppressing gonadotropins and contributing to anabolism in monkeys, with a potentially wider therapeutic index for human androgen replacement and male contraception.

This review analyzes how androgens impact sexual desire and reproductive behaviors, emphasizing molecular interactions, but provides no new clinical results.

This review discusses the nocebo effect in dermatology, highlighting its mechanisms, implications, and strategies to manage it, but does not provide new clinical research findings.

This review highlights the challenges in screening for steroid 5 alpha-reductase inhibitors and discusses significant variability in the effectiveness of finasteride and dutasteride, calling for standardized testing methods to develop safer, more specific inhibitors from herbal preparations.

This review discusses post-finasteride syndrome, emphasizing its serious psychological and cognitive symptoms and the need for more research and awareness in the medical community, but provides no new clinical findings.

This review discusses medical therapies for benign prostatic hyperplasia, highlighting the importance of personalizing treatments to individual patient needs and preferences.

This article presents guidelines developed by a multidisciplinary expert panel for the care of adolescent transgender and non-binary individuals with gender dysphoria, emphasizing individualized, affirmative care to enhance well-being and quality of life.

This review concludes that global literature supports the lipidosterolic extract of Serenoa repens as efficacious and safe for treating lower urinary tract symptoms, with some studies showing equivalence to common pharmacologic agents.

This article reviews the negative impact of hair loss on self-esteem and quality of life across cultures without presenting new findings.

This article reviews the congenital disorder aphallia, describing its rarity, clinical characteristics, and the normal hormonal and chromosomal profiles of affected individuals, but does not report new research findings.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

This review reports that while finasteride effectively treats androgenetic alopecia and benign prostatic hyperplasia, persistent adverse effects on sexual, psychological, and metabolic health have been noted, highlighting the need for ongoing research and careful risk assessment for safer clinical usage.

This study reviews new treatments for androgenetic alopecia, including cell-derived exosomes and investigational drugs, which show potential to improve hair density and quality but require more rigorous and standardized trials to confirm efficacy and safety.

This study suggests that 9-Octadecenoic acid (Z)-, 2,3-dihydroxypropyl ester from African Yam bean seeds may inhibit the human 5α-reductase II enzyme, potentially helping manage BPH, although further studies are needed.

This systematic review reported that among men taking finasteride for benign prostatic hyperplasia, total PSA levels decreased by 30% to 50%, and free PSA by up to 45%, with reductions in prostate volume and PSA density observed as well.

In this case study, a 35-year-old woman with persistent hair loss saw noticeable improvements after five weeks of Jalaukavacharana (Leech Therapy) and supportive Ayurvedic treatment, suggesting potential benefits of this approach for hair loss conditions.

This study reports that prostatitis, affecting many men aged 30 to 50, arises from diverse causes, including bacterial infections and pelvic pain syndromes, and requires treatment strategies specific to its type, such as antibiotics and lifestyle changes.

In this study, researchers examined androgen receptor activity in the adult mouse brain and found specific expression in key brain areas, which could inform understanding of cognitive side effects in humans undergoing androgen deprivation therapy for prostate cancer.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.

The document concludes that current hair loss treatments have limitations and suggests researching new treatments targeting different factors of hair loss.

This workshop review from the Australian Hair and Wool Research Society discusses findings in cutaneous biology and endocrinology but presents no new research results.

This review discusses the neurobiology of sexual function and reports no new results; the authors cover multiple endocrine and neurotransmitter influences on sexual desire, arousal, and orgasm stages.

This study supports the conclusion that the hormetic dose-response model is the most prevalent and fundamental model in biological and biomedical sciences, applicable to a wide range of clinical conditions.